Suppression of Ia antigen expression on gamma interferon treated macrophages infected with Ehrlichia risticii.
Ehrlichia risticii is an obligate intracellular bacterium of monocytes/macrophages. In this report, using immunofluorescence staining, flow cytometry, and Kolmogorov-Smirnov analysis of histograms, the response of P338D1 and peritoneal macrophages stimulated with recombinant murine interferon-gamma (rIFN-gamma) was examined for the expression of major histocompatibility complex Class II gene product (Ia) and effect of E. risticii infection on induction of Ia surface expression. Maximal expression of Ia by sham-infected P388D1 cells was observed 2 days post rIFN-gamma addition followed by a progressive decline. These stimulatory effects of rIFN-gamma were dose dependent. Relative to sham-infected P388D1 cells, the induction of Ia by rIFN-gamma (200 U ml-1) on E. risticii-infected P388D1 cells was significantly suppressed at each time point tested through Day 5 with maximal suppression of 88% occurring on Day 2. Similarly, the induction of Ia by rIFN-gamma on E. risticii-infected peritoneal macrophages was significantly suppressed by 77% (fluorescent microscopy) when compared to sham-infected peritoneal macrophages. The higher dose of rIFN-gamma (2000 U ml-1) failed to restore Ia surface expression by E. risticii-infected P388D1 cells. The suppression of Ia on P388D1 cells in response to RIFN-gamma was not related to the degree of infection of these cells by E. risticii. A soluble inhibitor substance was not demonstrable in the supernatant from E. risticii-infected cells, nor were inhibitor levels of prostaglandin E2 levels found in the supernatant. Suppression of surface Ia expression on the macrophage suggests a mechanism whereby I. risticii may evade T-lymphocyte recognition, hinder antigen-specific T-lymphocyte activation, and promote their own survival.
Messick
J B
JB
Department of Veterinary Pathobiology, College of Veterinary Medicine, Ohio State University, Columbus 43210.
Rikihisa
Y
Y
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D002474:Cell-Free System; D015232:Dinoprostone / Q000494:pharmacology; D004306:Dose-Response Relationship, Immunologic; D004536:Ehrlichia / Q000276:immunology*; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology* / Q000378:metabolism; D007108:Immune Tolerance / Q000187:drug effects*; D007371:Interferon-gamma / Q000494:pharmacology*; D007700:Kinetics; D007941:Leukemia P388; D008264:Macrophages / Q000187:drug effects / Q000276:immunology* / Q000382:microbiology; D051379:Mice; D008811:Mice, Inbred DBA; D010529:Peritoneal Cavity; D011994:Recombinant Proteins; D013491:Suppressor Factors, Immunologic / Q000502:physiology
D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II; D011994:Recombinant Proteins; D013491:Suppressor Factors, Immunologic; D007371:Interferon-gamma; D015232:Dinoprostone